L. Rusen

发表

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A

C. Négrier, C. Solomon, R. Klamroth, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

E. Santagostino, L. Boggio, K. Fischer, 2016, Blood.

BDDrFVIII (Moroctocog alfa [AF‐CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study

S. Arkin, J. Windyga, R. Gruppo, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326 )

W. B. Knowlton, O. Stasyshyn, B. Abbuehl, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant factor IX (BAX326 ) in previously treated paediatric patients with haemophilia B: a prospective clinical trial

O. Stasyshyn, B. Abbuehl, T. Urasiński, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B

O. Stasyshyn, T. Lissitchkov, J. Windyga, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Multicentre, randomized, open‐label study of on‐demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects

L. Valentino, J. Korth-Bradley, I. Elezović, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Effect of late prophylaxis in hemophilia on joint status: a randomized trial

C. Peterfy, C. Kempton, D. Raunig, 2017, Journal of thrombosis and haemostasis : JTH.

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

B. Konkle, T. Lissitchkov, M. Serban, 2007, Journal of thrombosis and haemostasis : JTH.

Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

C. Kempton, T. Lissitchkov, M. Manco‐Johnson, 2013, Journal of thrombosis and haemostasis : JTH.

PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A

K. Pasi, R. Klamroth, T. Lissitchkov, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical haemophilia Safe switching from a pdFIX ( Immunine ) to a rFIX ( Bax 3261 )

O. Stasyshyn, B. Abbuehl, M. Serban, 2014 .

Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

J. Mahlangu, Depei Wu, C. Truica, 2015, Journal of thrombosis and haemostasis : JTH.

Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study.

B. Kerlin, R. Ljung, V. Blanchette, 2020, Thrombosis Research.

Randomized, Controlled, Parallel-Group Trial of Routine Prophylaxis Versus On-Demand Treatment With rFVIII-FS in Adults With Severe Hemophilia A (SPINART).

C. Kempton, T. Lissitchkov, M. Manco‐Johnson, 2013 .

BAY 81‐8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial

R. Ljung, M. Mancuso, G. Kenet, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical experience with moroctocog alfa (AF‐CC) in younger paediatric patients with severe haemophilia A: Two open‐label studies

J. Korth-Bradley, K. Kavaklı, J. Fuiman, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings

V. Jiménez‐Yuste, J. Korth-Bradley, A. Cid, 2015, Thrombosis and Haemostasis.

Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study

O. Stasyshyn, T. Lissitchkov, J. Windyga, 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

E. Santagostino, L. Boggio, K. Fischer, 2016, Blood.

Efficacy and safety of a VWF/FVIII concentrate (wilate®) in inherited von Willebrand disease patients undergoing surgical procedures

C. Kessler, T. Lissitchkov, A. Srivastava, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

BDDrFVIII (Moroctocog alfa [AF‐CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study

S. Arkin, L. Rusen, A. O’Brien, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Multicentre, randomized, open‐label study of on‐demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects

L. Valentino, J. Korth-Bradley, I. Elezović, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Randomized, Prospective Clinical Trial of rFVIIa for Secondary Prophylaxis in Hemophilia Patients with Inhibitors.

B. Konkle, T. Lissitchkov, M. Serban, 2006 .